Table 1.
Characteristics of trials comparing ticagrelor to prasugrel
| Characteristic | ISAR-REACT 5 (PCI subgroup, n = 3377) | ISAR-REACT 5 (Non-PCI subgroup, n = 641) | PRAGUE-18 (n = 1230) | DUBIUS trial∗ (n = 438) | Bonello et al.25 (2015) (n = 213) |
REDUCE-MVI trial (n = 108) | Laine et al.26 (2014) (n = 100) |
Alexopoulos et al.24 (2012) (n = 55) |
RAPID trial (n = 50) |
|---|---|---|---|---|---|---|---|---|---|
| Age, y, mean | 64.6 | 64.8 | 61.8 | 65.0 | 60.7 | 60.6 | 63.8 | 59.4 | 67.0 |
| Women | 21.2 | 37.9 | 24.5 | 24.4 | 25.2 | 15.4 | 24 | 19.9 | 22.0 |
| Prior MI | 15.5 | 16.9 | 8.3 | 17.5 | 11.5 | — | — | — | 8.0 |
| DES | 89.5 | — | 65.2 | — | 96 | 100.0 | 79.5 | — | — |
| Index event | |||||||||
| Unstable angina | 8.2 | 36.3 | — | 21.0 | — | — | 19.4 | — | — |
| NSTEMI | 45.4 | 50.4 | 5.4 | 79.0 | 49.8 | — | 80.6 | — | — |
| STEMI | 46.5 | 13.3 | 89.5 | — | — | 100.0 | 100.0 | 100.0 | |
| MACE definition | All-cause death, MI, or stroke | CV death, nonfatal MI, or nonfatal stroke | Death from vascular causes, non-fatal MI, or non-fatal stroke | CV death, MI, urgent revascularization, and stroke | All cause death, MI | CV death, MI, and stroke | — | MI | |
| Major bleeding definition | BARC 3–5 | BARC 3–5 | BARC 3–5 | BARC 3–5 | —– | BARC 3–5 | — | TIMI Major | |
| Follow-up duration | 12 mo | 12 mo | 1 mo | 1 mo | 12 mo | in-hospital (mean, 3 d) | 5 d | in-hospital | |
Values are %, unless otherwise indicated.
BARC, Bleeding Academic Research Consortium; CV, cardiovascular; DES, drug-eluting stent; DUBIUS, Downstream vs Upstream Strategy for the Administration of P2Y12 Receptor Blockers In Non-ST Elevated Acute Coronary Syndromes With Initial Invasive Indication; ISAR-REACT 5, Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5; MACE, major adverse cardiac events; MI, myocardial infarction; NSTEMI, non-STEMI; PCI, percutaneous coronary intervention; PRAGUE-18, Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction; RAPID, Rapid Activity of Platelet Inhibitor Drugs; REDUCE-MVI, Reducing Microvascular Dysfunction in Revascularized STEMI Patients by Off-Target properties of Ticagrelor; STEMI, ST-segment elevation myocardial infarction; TIMI, Thrombolysis in Myocardial Infarction.
Baseline characteristics from the total DUBIUS trial cohort; only 30% of these patients were treated with PCI.